Non-alcoholic fatty liver disease (NAFLD)
eMERGE GHC/University of Washington Group
The KPWA/UW-led ovarian/uterine cancer phenotype has been validated at Mayo Clinic, the secondary phenotype development site. Validation results at both the primary and secondary sites were strong and the phenotype is ready for network wide implementation. The pseudo code document posted 11/30/2017 is correct as is and should be used by network sites for phenotype implementation. A validated data dictionary of covariates for this phenotype will be added to PheKB by 2/15/2018, but sites are encouraged to begin implementing the phenotype algorithm now.
Phenotyping algorithm for the identification of patients with type 1 or type 2 diabetes mellitus (DM) preoperatively using routinely available clinical data from electronic
Genetic variation that predicts white blood count (WBC) and it differential, a marker of the health of the immune system.
WBC is unique among the identified inflammatory predictors of chronic disease in that it has been routinely measured in healthy patients in an unbiased way for the duration of the electronic medical record data.